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Glucose transporter 2 (Glut2)-positive cells are sparsely distributed in brain and play an 
important role in the stimulation of glucagon secretion in response to hypoglycemia. We aimed 
to determine if Glut2-positive cells can influence another response to hypoglycemia, i.e., 
increased cerebral blood flow (CBF). CBF of adult male mice devoid of Glut2, either globally 
(ripglut1:glut2-/-) or in the nervous system only (NG2KO), and their respective controls were 
studied under basal glycemia and insulin-induced hypoglycemia using quantitative perfusion 
magnetic resonance imaging at 9.4T. The effect on CBF of optogenetic activation of 
hypoglycemia responsive Glut2-positive neurons of the paraventricular thalamic area was 
measured in mice expressing channelrhodopsin2 under the control of the Glut2 promoter. We 
found that in both ripglut1:glut2-/- mice and NG2KO mice CBF in basal conditions was higher 
than in their respective controls and not further activated by hypoglycemia, as measured in the 
hippocampus, hypothalamus and whole brain. Conversely, optogenetic activation of Glut2-
positive cells in the paraventricular thalamic nucleus induced a local increase in CBF similar to 
that induced by hypoglycemia. Thus, Glut2 expression in the nervous system is required for the 





A continuous supply of glucose from the systemic circulation to the brain is essential for 
sustained brain metabolism and function and any interruption of glucose delivery may lead to 
brain cell injury or death1, 2. Hypoglycemia is a state of energy deficit incompatible with the 
maintenance of normal brain function and therefore elicits numerous hormonal responses to 
restore euglycemia, including an increased secretion of epinephrine and glucagon3. In addition, 
hypoglycemia also induces an immediate elevation of cerebral blood flow (CBF) in regions 
associated with increased autonomic response, a response consistently observed not only in 
humans but also in other mammals1, 4, 5. A local increase in CBF is also required for increased 
delivery of glucose in regions with augmented synaptic activity observed for instance during 
hypoglycemia and prevents hypoglycemia-associated cognitive impairments4, 6. However, in 
diabetic patients the normal hypoglycemia-induced increase in blood flow becomes 
progressively impaired4, 7, 8 in association with development of hypoglycemia associated 
autonomic failure. 
 The mechanisms underlying the global increase of CBF upon hypoglycemia and how 
they become blunted in diabetes remains unclear. Experimental studies have suggested that the 
increased CBF upon insulin-induced acute hypoglycemia is comparable to the elevation of CBF 
at pharmacological doses of deoxyglucose9. Glucose responsive neurons activated by 
hypoglycemia, referred to as glucose inhibited (GI) neurons, have been characterized by 
electrophysiological recordings on acute brain slices and found to be present in several brain 
areas, in particular in the hypothalamus and brainstem10-12. Activation of GI neuron firing by 
hypoglycemia involves a decrease in glucose metabolism with the consequent activation of 
AMP-dependent protein kinase and closure of a chloride conductance, or of K+ leak channels13. 
In preceding studies we have shown that GI neurons from the nucleus tractus solitarius (NTS) 
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express the glucose transporter Glut2 and are involved in stimulating vagal nerve activity and 
glucagon secretion, linking hypoglycemia detection by the brain to the counterregulatory 
response14. More recently, we found that Glut2 neurons in the paraventricular thalamic nucleus 
(PVT) are also activated by hypoglycemia. These are glutamatergic neurons that project to the 
nucleus accumbens and when activated by hypoglycemia, Glut2 inactivation, or optogenetics 
they increase motivated sucrose seeking behavior in mice15. Immunohistological analysis of 
Glut2 expression as well as genetic tagging of Glut2-expressing cells revealed that Glut2 is 
expressed in relatively rare neurons, astrocytes and endothelial cells distributed in several brain 
areas16-19. As Glut2 expression has been consistently associated with glucose sensing capacity20, 
this suggests that central Glut2-expressing cells may form a global glucose surveillance 
network. Here, we tested the hypothesis that brain Glut2-expressing cells control CBF in 
response to hypoglycemia. 
 In order to measure CBF, we used the arterial spin labeling (ASL) magnetic resonance 
imaging (MRI) technique, which provides a non-invasive measurement of the blood flow in the 
brain21, 22 that is superior to other exogenous contrast-agent based techniques, e.g. 
autoradiography9, 23, positron emission tomography (PET24) and dynamic perfusion MRI25. 
Moreover, continuous ASL (CASL) using an actively-detuned two-coil system presents higher 
sensitivity and minimizes magnetization transfer effects and, thus, has been extensively used 
for brain studies in both rats21, 22 and mice26, 27.  Furthermore, the hypoglycemia-induced CBF 
increases measured in rats using the CASL technique28 were similar to those obtained from ex 
vivo tissues using a diffusible indicator (i.e. 4-iodo-[N-methyl-14C] antipyrine)5, 9. 
 Thus, the aim of this study was to compare CBF under basal glycemia and upon insulin-
induced hypoglycemia in Glut2-null mice and their controls using the CASL MRI technique.  
We also used an optogenetic approach to test the impact on regional blood flow of selectively 





All experiments were carried out with the approval of the Veterinary Office of Canton de Vaud, 
and were conducted according to the Federal and Local ethical guidelines, EXPANIM 
(Expérience sur animaux- SCAV, Service de la consommation et des affaires vétérinaires, 
Switzerland) and in compliance with ARRIVE guidelines (Animal Research: Reporting in Vivo 
Experiments) for how to REPORT animal experiments. We used mice with systemic Glut2 
gene inactivation and transgenic expression of Glut1 in pancreatic islet beta-cells to normalize 
glucose-stimulated insulin secretion (ripglut1;glut2-/- mice and their littermate controls: 
ripglut1;glut2+/- )29 and mice with inactivation of the Glut2 gene only in the central and 
peripheral nervous system Glut2 (glut2Δ/loxP;NesCre/+ (NG2KO) mice and their littermate 
controls: glut2delta/lox; or glut2+/lox;NesCre/+)30. All mice studied had been backcrossed on the 
C57BL/6 background. For the optogenetic study, we used mice expressing channelrhodopsin2 
in Glut2-positive cells (glut2-cre;Rosa26ChR2-YFP; mixed C57BL/6;SV129 background)14, 15, 
18.  
 For all experiments, adult male mice (10-15 weeks old) were used. Animals were 
collectively housed (maximum 5 individuals per cage) on a 12-hour light/dark cycle (lights on 
at 7 a.m.) and fed with a standard chow (Diet 3436, Provimi Kliba AG). 
 
MR Experiments 
For MR experiments, all mice were anesthetized in a chamber filled with 3% isoflurane mixed 
with air, which helped minimizing the effect of oxygen levels on CBF. Thereafter, the mice 
were placed in a home-built holder and fixed using one bite piece and two ear bars. Once mouse 
heads were secured, tail bleeds were sampled for blood glucose level measurements using a 
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glucose meter (Bayer Breeze2, Bayer Inc.), which requires a 1 µL volume per test and delivers 
a sufficient glucose range for our study, e.g. 0.6-33.3mmol/L. Through the entire studies, 
physiological conditions including respiration rate and rectal temperatures were monitored 
through an MR compatible monitoring system (SA Instruments, US) and maintained in the 
targeted range, i.e. 80-110 beats-per-minute and 36-37°C, by varying the percentage of 
isoflurane (i.e. 1-1.5%) and the temperature of circulating warm water, respectively. 
Immediately at the end of the MR experiments, glycemia was measured again from tail bleeds 
and blood samples were withdrawn from some animals to ensure that pH was 7.3-7.5, PaCO2 
35-45mmHg and PaO2>80mmHg, in order to prevent their vascular effects on CBF31.  
 The MR experiments were performed in a horizontal, 9.4T/26cm magnet (Agilent Inc., 
US), with a 12-cm-diameter gradient (400mT/m in 200µs) insert interfaced to a DirectDrive 
console (Vnmrj, Agilent Inc., USA). A 1H quadrature coil consisting of two geometrically 
decoupled 12-mm-inner-diameter loops, resonating at 400MHz, was used as a radio-frequency 
(RF) transceiver for MR imaging. An 8-mm-inner-diameter butterfly RF coil at 400MHz was 
used for arterial spin labeling. Both coils included PIN-diode based active-detuning circuits, 
controlled by a CASL pulse sequence via a home-built switch board26. 
 
Neurochemical profile of hippocampus and hypothalamus  
To assess potential effects of glut2 gene inactivation on brain and its intracellular glycemic state 
at basal glycemia, a localized 1H MR spectroscopy sequence was applied to two brain regions, 
e.g. hippocampus (~4µL) and hypothalamus (~4µL16-19), of five ripglut1;glut2-/- mice and five 
control littermates under basal (random fed) glycemia, as previously described32. This allowed 
assessing abundant metabolites involved in neurotransmission and metabolism from defined 
brain volumes, including all cells, extracellular space, and bloodstream. Cerebrospinal fluid 
contributes minimally to the measured metabolites in bilateral hypothalamus and even less so 
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in unilateral hippocampus32. Sufficient signal to noise ratios (SNRs>15) were achieved by 
averaging 160-320 scans for 1H MR spectra. The water signal (8 scans) was acquired from the 
identical volumes of interests for further quantification, as described below.  
 
Continuous arterial spin labeling (CASL) of cerebral blood flow (CBF) 
The CASL pulse sequence was implemented with a semi-adiabatic Spin-Echo Echo Planer 
Imaging (SE-EPI) sequence with both negative and positive reference scans by including 
additional labeling components, i.e. a 2.1-second hard RF pulse, a z-gradient (14mT/m) and 1 
second delay26. Each labeling plane was carefully selected based on serial anatomical neck 
images (gradient-echo, 0.4-mm slice thickness, 20×20mm2, RO×PE = 128×128, nt = 8).  
 Anatomical images of murine brains were acquired using a fast spin echo (FSE) sequence 
(TEeffective/TR=50/4000ms, a 20mm×20mm field of view (FOV), readout (RO)×phase-encode 
(PE)=256×256, 8 averages). Both first and second order shim terms were automatically adjusted 
over the murine brain (a 6´4´5mm3 volume of interest, VOI) using an EPI version of FASTMAP 
33. A localized water signal was acquired from the volume covering the entire brain to examine 
the field homogeneity within the VOI. Immediately after improving field homogeneity, 16 pairs 
of 4 or 8-segmented semi-adiabatic SE-EPI images were acquired to map cerebral blood flow 
(TE=42ms, FOV=23×15mm2, RO×PE=128×64, spectral width=200 kHz, 1.5-2.0 mm slice 
thickness)26. For CBF in response to hypoglycemia, the EPI image slices were carefully 
positioned by referencing to the dorsal edge of the ventral hippocampal commissure (vhc) at 
Bregma -0.8mm to have two MR image slices centered at Bregma 1mm and -2mm, respectively. 
The total acquisition time was approximately 6 or 13 minutes.  
 
CBF measurements under resting glycemia and insulin-induced hypoglycemia 
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To evaluate CBF responses upon insulin-induced hypoglycemia, ripglut1;glut2-/- mice (n=7) 
and their wild type counterparts (n=6) were studied at basal glycemia and following insulin-
induced hypoglycemia. Six NG2KO mice and six of their age-matched control littermates were 
similarly studied. 
 A cannula was placed in the femoral vein, and mice were placed in the holder for the 
CASL measurements and a first CBF determination in basal glycemic conditions was 
performed over a 20 minute period, as described above. Then, to induce hypoglycemia the 
animals along with the entire fixation system, including the RF coils, were carefully removed 
from the magnet and placed securely outside the magnetic field. A 1U/kg bolus of insulin 
(1U/ml, Lilly Inc. US) was given in 20 minutes. Once the hypoglycemic condition was reached, 
i.e. ≤2.5mmol/L, a minimal continuous rate of insulin (in the range of 2-4 mU/kg) was 
maintained, and animals were carefully placed back to the original position in the magnet. Right 
after relocating the original slice position based on both coronal and sagittal images, i.e. in a 
0.01mm precision with our existing MR system, field homogeneity was then slightly adjusted. 
Then, CBF measurements were performed on the nearly matching slice (e.g. a corresponding 
0.067% error to a 0.01mm shift of a 1.5-mm-thick slice) in the very same animals using the 
identical CASL parameters over a 20 minute period. A typical experimental layout is shown in 
Figure Sup 1. 
 The validity of the present protocol to study central effects of hypoglycemia on CBF 
relies on the absence of potential alterations of CBF secondary to peripheral cardiovascular 
changes. Isoflurane anesthesia minimally affects heart rate and pressure in mice 34. Likewise, 
hypoglycemia is unlikely to secondarily alter CBF in our experiments. Indeed, firstly, while 
hypoglycemia was shown to increase heart rate – but not blood pressure6, we observed in 
parallel bench experiments using the MouseOx® module (Starr Life Science Corp, USA) in 
three control mice undergoing an identical CBF protocol, that heart rate did not significantly 
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change during the experiment, i.e. between the basal and hypoglycemic periods (P>0.05), or 
from beginning to end of the basal period (457±75bpm vs. 482±46 bpm (mean±SD) 
respectively, p>0.05) and hypoglycemic phase (495±39 bpm and 506±36bpm, respectively, 
p>0.05). Secondly, CBF is highly autoregulated so that it remains independent of peripheral 
blood flow within a wide range of physiological cardiovascular states1, 31, and the observed 
heart rate ranges in our bench experiment were well within the physiological range for CBF 
autoregulation34. As CBF is altered by both hypercapnia and poor blood oxygenation31, 
appropriate PaCO2 and PaO2 values were maintained by controlling respiration rates in the 
range of 80-110 bpm by varying the delivery rate of isoflurane26. 
 
Optogenetics 
10 to 15 weeks old glut2Cre/+;rosa26ChR2loxP/+ (glut2Cre;rosa26ChR2lox/+) and 
glut2+/+;rosa26ChR2loxP/+ controls (rosa26ChR2lox/+) were used for in vivo optogenetics 
experiments. One week before the experiment the mice were placed in a stereotaxic frame 
(David Kopf Instruments, U.S.A) under isoflurane anesthesia. A custom made optical cannula 
made of a ceramic ferrule (Precision Fiber Products) and an optical fiber (0.39 NA, 200 µm 
core diameter) was lowered in the PVT using the following stereotaxic coordinates: AP -0.4 / 
ML +0.8 / DV -3.4 mm with a 10° angle to avoid any damage to the superior sagittal sinus. The 
optical cannula was secured on top of the skull with tissue adhesive (VetBond; 3M) and dental 
cement (Paladur; Heraeus-Kulzer). On the day of the experiment, the animals were prepared 
for CBF measurement, as described above. In addition, a DSPP laser (LRS-0473-GFM-00100-
05; Laserglow Technologies) placed outside the MRI scanner room was connected to the mice 
via a fiber optic patch cable plugged to the fiber cannula. The light stimulation protocol 
consisted of the delivery of 473 nm light pulses (10 ms light pulses at 20 Hz, 1 second on/1 
second off, 15 mW) for 15 min during the acquisition of CBF measurements. CBF was 
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monitored in anterior part of the PVT under basal and light-stimulated conditions. Basal CBF 
values were obtained by averaging CBF measurements before and after the optical stimulation.  
 
Data analysis 
The acquired 1H MR spectra were post-processed for quantification. Briefly, each spectrum was 
frequency-corrected, summed and prepared for further LCModel analysis. The water signal 
originating from the same VOIs without water suppression was assumed 80% for both 
hippocampal and hypothalamic tissues, as previously reported32. Data from mice with a basal 
(random fed) glycemia out of the 4-10mM range were excluded in order to avoid any potential 
effect of mild hypoglycemia and acute hyperglycemia on the neurochemical profiles35, 36.   
 CBF maps, in units of mL/100g/min, were derived by pair-wise pixel-by-pixel 
calculation of label and control semi-adiabatic SE-EPI images as previously described26, CBF = 	 λ&' ()*(+(+,	(./*0)()          [Eq. 1] 
where l is the blood-brain partition coefficient for water (0.9), T1 is the brain tissue longitudinal 
relaxation time (1.9 seconds at 9.4T), SC is the control imaging signal intensity, SL is the labeled 
image signal intensity, and a is the labeling efficiency of arterial spin labeling and assumed to 
be 0.8, as measured previously26. Regions of interests were manually drawn based on the 
acquired EPI images. For instance two brain regions with abundant Glut2 neurons, e.g. 
hippocampus and hypothalamus, and one low abundant Glut2 region, cortex, were assessed. The 
whole brain was also evaluated. The percent changes of cerebral blood flow were calculated 
based on the acquired CBF baselines under basal conditions, as above. 
 
Statistics 
Data are shown as mean ± SEM. Student t-test (paired/unpaired) was applied to single 
comparisons. In order to evaluate difference between genotypes or treatments, two-way 
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ANOVA was used with two major factors, e.g. genotype and region for CBF, genotype and 
metabolite for neurochemical profiles, and genotype and treatments for CBF changes. 
Bonferroni post-hoc tests were then applied. Differences were considered statistically significant 




Effects of systemic Glut2 inactivation on neurochemical profiles of both hippocampus and 
hypothalamus  
To evaluate the potential effects of Glut2 inactivation on brain neurochemical profiles, 
including energy substrates, such as glucose, lactate, and other metabolites, we acquired 1H MR 
spectra in the hippocampus and hypothalamus of ripglut1;glut2-/- mice under basal (random 
fed) condition in five ripglut1;glut2-/- mice and five control littermates. MR spectra were 
obtained from both brain regions with excellent quality, and distinct regional differences in 
metabolite levels (Figure 1). The glycemia before and at the end of the measurements were 
9.3±0.6 and 7.3±2.0mM, respectively (paired t-test p=0.34) for control mice and 6.1±0.2 vs. 
5.0±0.2mM (paired t-test p<0.03) for ripglut1;glut2-/- mice. Despite these glycemic differences 
between control mice and ripglut1;glut2-/- mice, which are due to renal glucose excretion in the 
absence of Glut2 from the proximal convoluted tubules, glucose levels in the hippocampus and 
hypothalamus were not different between strains (1.9±0.2 vs. 1.2±0.3 µmol/g in the 
hippocampus of control and mutant mice, respectively p=0.093; 2.2±0.2 vs. 1.5±0.6  µmol/g, 
in the hypothalamus of control and mutant mice, respectively, p=0.10). This was also the case 
for all the other measured metabolites, except for a significant increase of myo-inositol in the 
hippocampus of ripglut1;glut2-/- mice (Figure 2).  
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CBF of ripglut1;glut2-/- mice under basal glycemia and insulin-induced hypoglycemia 
For continuous ASL-based measurement of CBF, another group of ripglut1;glut2-/- mice was 
studied. Multi-slice SE-EPI images were obtained with minimal artifacts or distortion and 
preserved anatomical structures, which allowed identifying regions of interest, e.g. 
hippocampus, hypothalamus, cortex and whole brain.   
 In basal conditions, cerebral blood flow exhibited regional variations (Figure 3). A 
significantly higher CBF was observed in the hippocampus and hypothalamus of ripglut1;glut2-
/- mice as compared to control mice (Figure 3 A, Figure 4 A-D). When assessed in the cortex 
and the whole brain, no significant difference in CBF could be measured between strains. In 
control mice, blood glucose levels did not vary before and immediately after the CBF 
measurements (10.8±1.0mM vs. 10.3±1.5mM, respectively; paired t-test p=0.96); in 
ripglut1;glut2-/- mice glycemic levels tended to decrease (8.4±2.1mM vs. 5.7±1.6 mM, 
respectively; paired t-test p=0.19). 
 Next we determined CBF during insulin-induced hypoglycemia in ripglut1;glut2-/- mice 
(n=7) and their controls (n=6). In control mice, hypoglycemia (1.5±0.1mM, Figure 4 E) 
significantly elevated CBF, (Figure 3, Figure 4 A-D,F) by 28±10% in hippocampus, 38±10% 
in hypothalamus, 33±6% in cortex and 21±6% in whole brain. In ripglut1;glut2-/- mice, 
hypoglycemia (1.0±0.1 mM, Figure 4 E,F) did not increase CBF except in the cortex where a 
small increase (5±3%) could be measured.  
 
CBF of NG2KO mice under resting/basal glycemia and acute hypoglycemia 
To exclude potential contribution from peripheral Glut2 and specifically assess the role of 
nervous system Glut2 on CBF, we studied another mouse model, the NG2KO mice30 in the 
basal state and upon insulin-induced hypoglycemia (Figure 3B), as described above.  
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 In basal conditions, NG2KO mice and their controls (six of each) had similar glycemic 
levels, i.e. 6.9±0.6mM vs. 9.2±1.7mM (unpaired t-test p=0.30). NG2KO mice displayed 
significantly higher CBF than controls in the hypothalamus and the whole brain, but not in the 
hippocampus and cortex (Figure 5A-D).  
 Upon insulin-induced hypoglycemia (Figure 5 E), control mice displayed increased 
CBF over all regions analyzed, e.g. 14±3% in hippocampus, 24±4% in hypothalamus, 18±5% 
in cortex and 15±3% in brain (Figure 5 A-D,F). In contrast, hypoglycemia in NG2KO mice 
(Figure 5 E), failed to increase CBF in the hippocampus (-2±4%), in the hypothalamus (-7±3%) 
and in the entire brain (-5±2%), with, however, a small increase in the cortex (11±7%) (Figure 
5 A-D,F). The higher CBF measured in both the ripglut1;glut2-/- mice and NG2KO mice in the 
basal state as compared to their respective controls suggests that inactivation of Glut2, by 
preventing glucose uptake, leads to an intracellular state of hypoglycemia sufficient to 
maximally activate the Glut2 cells involved in CBF control. 
 
Optogenetic activation of PVT Glut2 neurons increases CBF  
To directly evaluate the role of Glut2-expressing cells in the regulation of CBF, we determined 
whether optogenetic activation of Glut2-neurons of the PVT could elicit a local increase in 
CBF. We previously reported that these PVT Glut2 neurons form a homogenous population of 
glucose-inhibited neurons that control motivated sucrose seeking behavior15. Here, we 
equipped glut2Cre;rosa26ChR2lox/+ mice and littermates not expressing channelrhodopsin with 
a fiber-optic cannula in the PVT. CASL measurements were performed in the basal state and 
during optical stimulation. Light stimulation of channelrhodopsin-expressing Glut2-neurons 
increased local CBF in the PVT by 28±4% (Figure 6); no such increase was observed in control 
(1±3%, Figure 6).  No differences in glycemia were found between the two groups, e.g. 
8.8±0.6mM in glut2Cre;rosa26ChR2lox/+ mice and 9.6±0.8mM in controls (unpaired t-test 
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p=0.53) before CBF measurements, and 6.3±0.6 vs. 8.3±1.8mM (unpaired t-test p=0.33) at the 
end of the measurements.  
 
DISCUSSION 
The present study shows that systemic inactivation of Glut2 or its inactivation only in the 
nervous system increases CBF in basal glycemic conditions but prevents its increase in response 
to insulin-induced hypoglycemia. This was observed in the whole brain and specifically in the 
hypothalamus and hippocampus, and to a lesser extent in the cortex. In addition, optogenetic 
activation of Glut2-neurons of the PVT was sufficient to increase local CBF. This study, thus, 
identifies Glut2 expression in brain cells as a critical determinant of cerebral blood flow 
response to hypoglycemia.  
 Previous immunohistochemical studies reported that Glut2 is expressed in many brain 
regions where it is expressed by sparsely distributed neurons, glial or endothelial cells16, 17. 
Mice expressing a fluorescent reporter protein under the control of the Glut2 locus show a 
similar distribution of Glut2-expressing cells18. These central Glut2 expressing cells were found 
to be required for glucose sensing and the control of various aspects of glucose homeostasis 
and feeding behavior19, 20, 37. In particular, we showed that central Glut2-dependent glucose 
sensing cells are required for the control of glucagon secretion in response to hypoglycemia18, 
19, 38. 
 In the present study, we extended these studies to assess the role of Glut2 expressing 
cells in the CBF response to hypoglycemia using the non-invasive MR techniques. Absence of 
Glut2 expression in ripglut1;glut2-/- mice had no effect on brain metabolites levels, impacting 
only slightly myo-inositol in the hippocampus but not in the hypothalamus. Notably, glucose 
levels in these two brain regions of Glut2-null mice were in the 1~2µmol/g range at euglycemia, 
in agreement with the fact that glucose transport through brain capillaries, a process that 
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depends largely on Glut1 expression in endothelial cells, represents the rate-limiting step for 
establishing parenchymal glucose levels39. In basal conditions, CBF was slightly, but 
significantly elevated in the hypothalamus of ripglut1;glut2-/- and NG2KO mice and in the 
hippocampus of ripglut1;glut2-/- mice when compared to their respective control littermates. 
Such increases in blood flow could not be explained by hypercapnia31 or poor blood 
oxygenation since throughout the entire studies we maintained their respiration rates in the 
range of 80-110 bpm by varying the delivery rates of isofluorane that ensured appropriate 
PaCO2 and PaO2 values. Moreover, these CBF increases were seen despite the fact that we used 
isoflurane, an anesthetic vasodilator40-42, which can raise all measured blood flow values and 
thus might narrow the CBF differences between strains. Since we excluded animals with 
moderate acute hyperglycemia, which occurred occasionally in controls but less so in 
ripglut1;glut2-/- mice, plausible CBF variations43-46 were ruled out from these CBF differences 
between strains.   
 Upon hypoglycemia, control mice displayed a marked increase in CBF in the cortex, the 
hippocampus and the hypothalamus, where the highest increase was observed. The increase in 
CBF induced by hypoglycemia was slightly lower in the NG2KO control group as compared 
to the ripglut1;glut2-/- control group; this may be attributed to slightly higher hypoglycemic 
levels of NG2KO controls compared to the ripglut1:glut2-/- control group (~1.8mM vs. 1.5 mM, 
unpaired t-test p=0.09), similar to observations in rats9. It is striking that the absence of Glut2 
expression in both mouse models studied led to the same increase in CBF in the basal state and 
the absence of response during insulin-induced hypoglycemia, except for a small increase in 
the cortex. The brain as a whole showed a markedly blunted CBF response in both mouse 
models. The lower suppression of CBF in the cortex is consistent with a lower vulnerability to 
hypoglycemia of the cortical tissue compared to other brain regions1, 47-49 suggesting that 
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whereas Glut2-dependent sensing is critical for adjusting CBF in many brain areas, other 
hypoglycemia detection mechanisms may operate in the cortex.  
 Our optogenetics experiments showed that activation of channelrhodopsin-expressing 
Glut2-neurons of the PVT led to a robust increase in local CBF, similar in magnitude to that 
obtained following insulin-induced hypoglycemia. These PVT Glut2 neurons have previously 
been described to control motivated feeding behavior through their projection to the nucleus 
accumbens15, a response that is activated by hypoglycemia or by Glut2 inactivation. Whether 
the same neurons control feeding behavior and CBF is not known. From our present 
experiments, we do not know if activation of PVT Glut2 neurons increase CBF also in the 
nucleus accumbens where their projections form a very dense network. Nevertheless, the fact 
that these PVT Glut2 neurons are glutamatergic suggest that they control CBF through the 
release of glutamate, which has been reported to be a key signal to trigger the production of 
various vasodilators by astrocytes and neurons1.  
 The observation that in the absence of Glut2 the basal state CBF is high and not further 
increased by hypoglycemia is analogous to our previous report that plasma glucagon levels 
during euglycemic clamps are higher in ripglut1;glut2-/- mice than in control mice and are not 
further increased by hypoglycemia38. This, therefore, suggests that in the absence of Glut2, the 
hypoglycemia-sensing cells that normally express this transporter can no longer take up 
glucose, thereby causing an intracellular state of hypoglycemia, which maintains the cells in an 
active state. The consequences are hyperglucagonemia and higher CBF in basal glycemic 
conditions. This also indicates that absence of Glut2 from these sensing cells is not compensated 
by expression of another glucose transporter. In a previous study19, we also showed 
hypoglycemia-induced glucagon secretion could be restored in ripglut1;glut2-/- mice by 
transgenic expression of Glut2 in astrocytes but not neurons. Here, we show that, at least in the 
PVT, Glut2-neurons can directly control CBF when activated by optogenetics. Whether CBF 
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and glucagon responses depend on Glut2 expression by different cell types, neurons vs. 
astrocytes, or whether hypoglycemia sensing in different brain regions rely on different cellular 
mechanisms that similarly control CBF and glucagon secretion is not known. However, our 
studies of Glut2 neurons of the PVT15 and the NTS14 showed that, although they are both 
activated by hypoglycemia, the PVT neurons are glutamatergic and the NTS ones are 
GABAergic. Thus, there is probably a multiplicity of hypoglycemia sensing modalities, which 
control various physiological functions. These could be investigated using optogenetic 
approaches as used here to selectively activate the Glut2 neurons of the PVT. 
 Collectively, our data show that Glut2 expression by brain cells is required for the 
control CBF in response to variations in glucose concentrations. These cells could be neurons, 
as shown for the PVT Glut2 neurons activated by optogenetics. But they could also be 
astrocytes, as these cells have been shown to also be involved in Glut2-dependent 
counterregulation19. One interesting aspect of these findings is that Glut2 cells are present in 
most brain areas as dispersed cells with, however, a distinctly low abundance in the cortex, 
where sparse nerve terminals have been observed17. These Glut2-expressing cells may, 
therefore, form a global monitoring system that detect falls in glycemia and trigger area-specific 
increases in blood flow. More work is required to fully understand how activation of these cells 
increases CBF. However, as Glut2 PVT neurons are glutamatergic and glutamate plays a critical 
role in controlling vasodilation 1, glutamate release may be a key mediator of increased CBF. 
Our mouse models may be used to further dissect the link between hypoglycemia detection and 
increased CBF.  
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Figure 1: MR spectra of mouse brain hippocampus and hypothalamus 
Localized MR spectra of hippocampus (red voxel in top MR image) and hypothalamus (yellow 
voxel in bottom MR image). Abbreviations: Gln, glutamine; Glu, glutamate; tCr, total creatine; 
GABA, g-aminobyutraric acid;  myo-Ins, myo-inositol; NAA, N-acetyl-aspartate; Mac, 
macromolecule; Lac, lactate. 
 
Figure 2: Neurochemical profiles of hippocampus and hypothalamus. 
Neurochemical profiles of hippocampus (Top) and hypothalamus (Bottom) of ripglut1;glut2-/- 
mice (KOG2, solid black bars, n=5) and their age-matched controls (Cont, in white bars, n=5) 
recorded in the basal state, revealed very minimal changes in ripglut1;glut2-/- (KOG2) mice 
except a small increase of myo-inositol (myo-Ins, arrow) in hippocampus (genotype: 
F(1,192)=20.72, p-value<0.0001, metabolite: F(23,192)=957.4, p-value<0.0001, interaction, 
F(23,192)=2.209, p-value=0.002, Two-way ANOVA followed by the Bonferroni post-tests P-
value<0.01). Abbreviations: alanine (Ala), ascorbate (Asc), aspartate (Asp), beta-
hydroxybutryrate (bHB), creatine (Cr), myo-inositol (myo-Ins), g-aminobutryric acid (GABA), 
glucose (Glc), Glutamine (Gln), glutamate (Glu), glycine (Gly), glycerophoshocholine (GPC), 
glutathione (GSH), lactate (Lac), macromolecule, Mac, N-acetyl-aspartate (NAA), N-acetyl-
aspartyl-glutamate (NAAG), phosphocholine (PCho), phosphocreatine (PCr), 
phosphatidylethanolamines (PE), and taurine (Tau). NAA+NAAG, Glu+Gln, GPC+PCho, 
Cr+PCr and myo-Ins+Tau were included for statistical analysis but not displayed here. Error 
bars were SEMs. 
 
Figure 3: Cerebral blood flow color maps.  
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Typical CBF maps of ripglut1;glut2-/- mice (KOG2 in A) and NG2KO  mice (B) mice and their 
corresponding control littermates in basal conditions (basal, left column) and during insulin-
induced hypoglycemia (hypo, right column). The typical CBF maps (mL/100g/min) at Bregma 
1 mm were scaled to colors (see side bars). 
 
Figure 4.  Impaired activation of CBF in ripglut1glut2-/- mice during insulin-induced 
hypoglycemia. 
The CBF values (ml/100g/min) of ripglut1glut2-/- (KOG2) mice and their control littermates 
(Cont) were measured under basal glycemic condition and insulin-induced hypoglycemia in 
different brain regions: (A) cortex, (B) hypothalamus, (C) hippocampus and (D) whole brain. 
(E) Glycemic levels of control and ripglut1glut2-/- mice under basal glycemic condition and 
upon insulin-induced hypoglycemia. (F) Changes in CBF in the indicated brain regions of 
control and ripglut1glut2-/- mice under insulin-induced hypoglycemia, expressed as percent of 
basal CBF values. Statistical significance: * p<0.05, ** p<0.01, *** p<0.001, comparing 
treatments (two-way RM ANOVA with the Bonferroni post-tests),, e.g. basal and hypo, in the 
same genotype groups. † p<0.05, †† p<0.01, ††† p<0.001, comparing genotypes, e.g. KOG2 
vs. Cont, under the same glycemic conditions (genotype and region factors, two-way ANOVA 
with the Bonferroni post-tests). Error bars were SEMs. 
When compare basal vs. hypo in the same genotype groups (A-D), two-way RM ANOVA was 
applied. Cont. treatment: F(1,20)=52.73, p-value<0.0001, regions: F(3,20)=1-.81, p-
value=0.0002, interaction: F(3,20)=0.7462, p-value=0.5372;  K2GO. treatment: F(1,24)=1.799, 
p-value=0.1924, regions: F(3,24)=6.181, p-value=0.0029, interaction: F(3,24)=2.4, p-
value=0.0927. To compare genotype (A-D), two-way ANOVA was applied with genotype and 
region factors at basal and hypo conditions. Basal: genotype, F(1,44)=20.01, p-value<0.0001; 
region, (F(3,44)=13.04, p-value<0.0001; and interaction, F(3,44)=0.4813, p-value=0.6970; 
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hypo: genotype , F(1,44)=0.3470, p-value=0.5588; region,  F(3,44)=11.12, p-value<0.0001;  
interaction, F(3,44)=0.3573, p-value=0.7841. In F, genotype: F(1, 44)=28.71, p-value<0.0001, 
region: F(3, 44)=1.319, p-value=0.2804, interaction: F(3, 44)=1.408, p-value=0.2531. Error 
bars were SEMs. 
 
Figure 5: Impaired activation of CBF in NG2KO  mice during insulin-induced 
hypoglycemia. 
The CBF values (ml/100g/min) of NG2KO  mice (n=6) and their control littermates (Cont, n=6) 
were measured under basal glycemic condition and insulin-induced hypoglycemia in different 
brain regions: (A) cortex, (B) hypothalamus, (C) hippocampus and (D) whole brain. (E) 
Glycemic levels of control and NG2KO mice under basal glycemic condition and upon insulin-
induced hypoglycemia. (F) Changes in CBF in the indicated brain regions of control and 
NG2KO mice under insulin-induced hypoglycemia, expressed as percent of basal CBF values. 
Statistical significance: * p<0.05, ** p<0.01, *** p<0.001, comparing treatments (two-way RM 
ANOVA with the Bonferroni post-tests), e.g. basal and hypo, in the same genotype groups. † 
p<0.05, †† p<0.01, ††† p<0.001, comparing genotypes, e.g. NG2KO vs. Cont, under the same 
glycemic conditions (genotype and region factors, two-way ANOVA with the Bonferroni post-
tests). Error bars were SEMs. 
To compare basal vs. hypo in the same genotype groups (A-D), two-way RM ANOVA was 
applied (treatment and region). Cont: treatment, F(1,20)=79.34, p-value<0.0001; regions, 
F(3,20)=3.862, p-value=0.0249; interaction, F(3,20)=1.028, p-value=0.4013; Subjects 
(matching) p-value=0.0002;  NG2KO: treatment, F(1,20)=0.007026, p-value=0.934; regions, 
F(3,20)=4.919, p-value=0.0102; interaction, F(3,20)=4.274, p-value=0.0174; Subjects 
(matching), p-value=0.0098. To compare genotype (A-D), two-way ANOVA was applied with 
genotype and region factors at basal and hypo conditions. Basal: genotype, F(1,40)=22.61, p-
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value<0.0001; region, (F(3,40)=8.249, p-value=0.0002; and interaction, F(3,40)=0.9113, p-
value=0.4442; hypo: genotype , F(1,40)=1.252, p-value=0.2698; region,  F(3,40)=6.802, p-
value=0.0008;  interaction, F(3,40)=0.6181, p-value=0.6074. In F (genotype and region 
factors), genotype: F(1,40)=36.43, p-value<0.0001, interaction: F(3,40)=2.811, p-
value=0.0516, region: F(3,40)=1.940, p-value=0.1387. 
 
Figure 6: Optogenetic activation of Glut2 neurons of the PVT increases local CBF. 
Glut2 neurons of the PVT expressing channelrhodopsin were stimulated by light during CBF 
measurements. (A) Anatomical MRI images. Squares indicate the location of the PVT. (B) 
light-induced CBF increase in mice expressing channelrhodopsin (Glut2-ChR) in Glut2 cells 
(n=5) but not in control mice (Cont) not expressing channelrhodopsin (n=6). Error bars were 
SEMs. Student unpaired t-test p value was 0.004. 
 
 
 
 






